PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment

被引:104
作者
Cugno, Massimo [1 ]
Borghi, Alessandro [2 ]
Marzano, Angelo V. [3 ]
机构
[1] Univ Milan, Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Dipartimento Fisiopatol Med Chirurg & Trapianti,M, Via Pace 9, I-20122 Milan, Italy
[2] Univ Ferrara, Dipartimento Sci Med, Sez Dermatol & Malattie Infett, Ferrara, Italy
[3] Univ Milan, Osped Maggiore Policlin, IRCCS Fdn Ca Granda, Dipartimento Fisiopatol Med Chirurg & Trapianti,U, Milan, Italy
关键词
SUPPURATIVE HIDRADENITIS SYNDROME; INFLAMMATORY-BOWEL-DISEASE; ALDRICH-SYNDROME PROTEIN; PSTPIP1 GENE MUTATION; NECROSIS-FACTOR-ALPHA; PYODERMA-GANGRENOSUM; PYOGENIC ARTHRITIS; AUTOINFLAMMATORY DISEASES; NEUTROPHILIC DERMATOSES; ACNE SYNDROME;
D O I
10.1007/s40257-017-0265-1
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis usually manifesting as skin ulcers with undermined erythematous-violaceous borders. It may be isolated, associated with systemic conditions or occurring in the context of autoinflammatory syndromes such as PAPA (pyogenic arthritis, PG and acne), PASH (PG, acne and suppurative hidradenitis) or PAPASH (pyogenic arthritis, acne, PG and suppurative hidradenitis). From a physiopathological point of view, all these conditions share common mechanisms consisting of over-activation of the innate immune system leading to increased production of the interleukin (IL)-1 family and 'sterile' neutrophil-rich cutaneous inflammation. From a genetic point of view, a number of mutations affecting the proteins of the inflammasome complex (the molecular platform responsible for triggering autoinflammation) or the proteins that regulate inflammasome function have been described in these disorders. As these debilitating entities are all associated with the over-expression of IL-1 and tumour necrosis factor (TNF)-alpha, biological drugs specifically targeting these cytokines are currently the most effective treatments but, given the emerging role of IL-17 in the pathogenesis of these syndromes, IL-17 antagonists may represent the future management of these conditions.
引用
收藏
页码:555 / 562
页数:8
相关论文
共 81 条
[1]  
Agarwal S, 2008, J RHEUMATOL, V35, P515
[2]   Longest Form of CCTG Microsatellite Repeat in the Promoter of the CD2BP1/PSTPIP1 Gene Is Associated with Aseptic Abscesses and with Crohn Disease in French Patients [J].
Andre, Marc F. J. ;
Aumaitre, Olivier ;
Grateau, Gilles ;
Chamaillard, Mathias ;
Costedoat-Chalumeau, Nathalie ;
Cardoso, Marie-Celeste ;
Henry-Berger, Joelle ;
Ramakrishna, Balakrishnan S. ;
Delpech, Marc ;
Piette, Jean-Charles ;
Creveaux, Isabelle .
DIGESTIVE DISEASES AND SCIENCES, 2010, 55 (06) :1681-1688
[3]   The Wiskott-Aldrich syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological synapse [J].
Badour, K ;
Zhang, JY ;
Shi, F ;
McGavin, MKH ;
Rampersad, V ;
Hardy, LA ;
Field, D ;
Siminovitch, KA .
IMMUNITY, 2003, 18 (01) :141-154
[4]   Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome [J].
Braun-Falco, Markus ;
Kovnerystyy, Oleksandr ;
Lohse, Peter ;
Ruzicka, Thomas .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (03) :409-415
[5]   Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra [J].
Brenner, M. ;
Ruzicka, T. ;
Plewig, G. ;
Thomas, P. ;
Herzer, P. .
BRITISH JOURNAL OF DERMATOLOGY, 2009, 161 (05) :1199-1201
[6]   Pyoderma Gangrenosum, Acne Conglobata, Suppurative Hidradenitis, and Axial Spondyloarthritis Efficacy of Anti-Tumor Necrosis Factor α Therapy [J].
Bruzzese, Vincenzo .
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2012, 18 (08) :413-415
[7]   IL-17 Blockade in Psoriasis [J].
Burkett, Patrick R. ;
Kuchroo, Vijay K. .
CELL, 2016, 167 (07) :1669-1669
[8]   PSTPIP1 gene mutation in a pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome [J].
Calderon-Castrat, X. ;
Bancalari-Diaz, D. ;
Roman-Curto, C. ;
Romo-Melgar, A. ;
Amoros-Cerdan, D. ;
Alcaraz-Mas, L. A. ;
Fernandez-Lopez, E. ;
Canueto, J. .
BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (01) :194-198
[9]   Pyoderma gangrenosum [J].
Callen, JP .
LANCET, 1998, 351 (9102) :581-585
[10]   The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum [J].
Caproni, M. ;
Antiga, E. ;
Volpi, W. ;
Verdelli, A. ;
Venegoni, L. ;
Quaglino, P. ;
Fabbri, P. ;
Marzano, A. V. .
BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (01) :275-278